IL4I1-driven AHR signature: a new avenue for cancer therapy  

作　　者：Zuli Wang Tiansheng Li Chao Mao Wenliang Liu Yongguang Tao 

机构地区：[1]NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism,Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,Hunan,China [2]Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education,Cancer Research Institute,Central South University,Changsha,Hunan,China [3]Department of Thoracic Surgery,Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer,Second Xiangya Hospital,Central South University,Changsha,Hunan,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第4期1086-1087,共2页信号转导与靶向治疗（英文）

基　　金：This work was supported by the National Natural Science Foundation of China[81672787,82072594,Y.T.,81972638,W.L.,82002916,C.M.];China Postdoctoral Science Foundation[2019M652804,CM.];Natural Science Foundation of Hunan Province[2020JJ5790,C.M.];Hunan Provincial Key Area R&D Programs[2019SK2253,Y.T.];Postdoctoral Foundation of Central South University[220372,C.M.];Shenzhen Science and Technology Program[KQTD20170810160226082];Shenzhen Municipal Government of China[JCYJ20180507184647104].

摘　　要：Aryl hydrocarbon receptor(AHR)was considered to be an important pan-tumor therapeutic target,but small molecule inhibitors targeting AHR target gene ID01 have failed in clinical trials.The recent paper published in Cell by Opitz et al.explained the failure of previous clinical trials and identified new therapeutic targets(Fig.1).

关 键 词：SIGNATURE explained identif 

分 类 号：R730.5[医药卫生—肿瘤]